AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
ApexOnco Front Page
Recent articles
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
The company might have blown Enliven out of the water.
Pfizer reveals the discontinuation of PF-08046044.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
It’s less about being fast, more about producing a better product.
The company will try to get the Komzifti QTc prolongation warning removed.
